Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

AZNAstraZenecaRunning, no new patients

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Locally Advanced (Inoperable) or Metastatic Breast Cancer

0Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

No warning signs right now. That's why the score is 0.

Score over time

Stage
Phase 3
Patients
818 (final count)
Started
Apr 16, 2020
Main results expected
May 9, 2023
Fully finished
Jun 22, 2026
Results posted
Oct 27, 2025

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Progression Free Survival: Overall Population (Months) in the Global Cohort

    Measured over: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  • Progression Free Survival: Overall Population (Percentage) in the Global Cohort

    Measured over: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  • Progression Free Survival: Altered Population (Months) in the Global Cohort

    Measured over: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

  • Progression Free Survival: Altered Population (Percentage) in the Global Cohort

    Measured over: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

  • Progression Free Survival: Overall Population (Months) in the China Cohort

    Measured over: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  • Progression Free Survival: Overall Population (Percentage) in the China Cohort

    Measured over: Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.

  • Progression Free Survival: Altered Population (Months) in the China Cohort

    Measured over: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

  • Progression Free Survival: Altered Population (Percentage) in the China Cohort

    Measured over: Assessed every 8 weeks for the first 2 years following objective disease progression or treatment discontinuation and then every 12 weeks.

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • none

Raw record changes

  • none yet

Trial ID NCT04305496 · record last updated 2026-04-30 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT04305496) ↗